BioSpace News Archive

Fourth-Quarter 2020 Worldwide Sales Were $12.5 Billion, an Increase of 5% Fourth-Quarter 2020 GAAP Loss per Share Was $0.83, Reflecting Charges Related to Acquisitions and Intangible Asset Impairments; Fourth-Quarter Non-GAAP EPS Was $1.32 Full-Year 2020 Worldwide Sales Were $48.0 Billion, an Increase of 2%; Excluding the Impact from Foreign Exchange, Sales Grew 4%

Reports fourth quarter 2020 revenue of $8.5 million, GAAP diluted EPS of $0.05 and non-GAAP diluted EPS of $0.07 Reports combined cash and investments of $52.0 million as of December 31, 2020

Angiotensin Therapeutics Inc. (“Angiotensin” or the “Company”), a privately-held biopharmaceutical company focused on developing breakthrough therapies to treat COVID-19, Acute Kidney Injury (AKI), and Chronic Kidney Disease (CKD), today announced the publication A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-Cov-2

GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—today announced the addition of a game-changing adaptive therapy, the Ethos™.

- 23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience, and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development - Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe’s consumer health and therapeutics businesses

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Thursday, February 18, 2021 at 11:00am ET

Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19 th Annual South Beach Symposium Additional Virtual Posters Highlight Data on DecisionDx® DiffDx™-Melanoma and DecisionDx®-SCC

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 11, 2021 at 11:00 AM ET.

Also known as genome editing with engineered nucleases, genome editing is a method of altering DNA within a cell in a safe manner.

The global market for high-resolution melting analysis is gaining momentum on account of the advancements in molecular biology.